| Inhibition of the hedgehog pathway in advanced basal-cell carcinoma DD Von Hoff, PM LoRusso, CM Rudin, JC Reddy, RL Yauch, R Tibes, ... New England Journal of Medicine 361 (12), 1164-1172, 2009 | 1355 | 2009 |
| Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449 CM Rudin, CL Hann, J Laterra, RL Yauch, CA Callahan, L Fu, T Holcomb, ... New England Journal of Medicine 361 (12), 1173-1178, 2009 | 1220 | 2009 |
| Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma RL Yauch, GJP Dijkgraaf, B Alicke, T Januario, CP Ahn, T Holcomb, ... Science 326 (5952), 572-574, 2009 | 1018 | 2009 |
| Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors L Gandhi, DR Camidge, M Ribeiro de Oliveira, P Bonomi, D Gandara, ... Journal of clinical oncology 29 (7), 909-916, 2011 | 666 | 2011 |
| Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors PM LoRusso, CM Rudin, JC Reddy, R Tibes, GJ Weiss, MJ Borad, ... Clinical cancer research 17 (8), 2502-2511, 2011 | 631 | 2011 |
| Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer CM Rudin, CL Hann, EB Garon, M Ribeiro de Oliveira, PD Bonomi, ... Clinical Cancer Research 18 (11), 3163-3169, 2012 | 623 | 2012 |
| A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC HP Mohammad, KN Smitheman, CD Kamat, D Soong, KE Federowicz, ... Cancer cell 28 (1), 57-69, 2015 | 510 | 2015 |
| Pneumonitis in non–small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors K Suresh, KR Voong, B Shankar, PM Forde, DS Ettinger, KA Marrone, ... Journal of Thoracic Oncology 13 (12), 1930-1939, 2018 | 371 | 2018 |
| Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer MC Pietanza, SN Waqar, LM Krug, A Dowlati, CL Hann, A Chiappori, ... Journal of Clinical Oncology 36 (23), 2386-2394, 2018 | 363 | 2018 |
| Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians guideline CM Rudin, N Ismaila, CL Hann, N Malhotra, B Movsas, K Norris, ... Journal of Clinical Oncology 33 (34), 4106-4111, 2015 | 350 | 2015 |
| Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–small cell lung cancer B Shankar, J Zhang, AR Naqash, PM Forde, JL Feliciano, KA Marrone, ... JAMA oncology 6 (12), 1952-1956, 2020 | 338 | 2020 |
| Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032 N Ready, AF Farago, F de Braud, A Atmaca, MD Hellmann, JG Schneider, ... Journal of Thoracic Oncology 14 (2), 237-244, 2019 | 329 | 2019 |
| Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer V Anagnostou, PM Forde, JR White, N Niknafs, C Hruban, J Naidoo, ... Cancer research 79 (6), 1214-1225, 2019 | 281 | 2019 |
| Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort NE Ready, PA Ott, MD Hellmann, J Zugazagoitia, CL Hann, F de Braud, ... Journal of Thoracic Oncology 15 (3), 426-435, 2020 | 274 | 2020 |
| Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II … D Morgensztern, B Besse, L Greillier, R Santana-Davila, N Ready, ... Clinical Cancer Research 25 (23), 6958-6966, 2019 | 268 | 2019 |
| NCCN guidelines insights: small cell lung cancer, version 2.2018 GP Kalemkerian, BW Loo, W Akerley, A Attia, M Bassetti, Y Boumber, ... Journal of the National Comprehensive Cancer Network 16 (10), 1171-1182, 2018 | 265 | 2018 |
| The role of vena caval filters in the management of venous thromboembolism CL Hann, MB Streiff Blood reviews 19 (4), 179-202, 2005 | 261 | 2005 |
| Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology AKP Ganti, BW Loo, M Bassetti, C Blakely, A Chiang, TA D'Amico, ... Journal of the National Comprehensive Cancer Network 19 (12), 1441-1464, 2021 | 256 | 2021 |
| Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer CL Hann, VC Daniel, EA Sugar, I Dobromilskaya, SC Murphy, L Cope, ... Cancer research 68 (7), 2321-2328, 2008 | 247 | 2008 |
| DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2 JT Poirier, EE Gardner, N Connis, AL Moreira, E De Stanchina, CL Hann, ... Oncogene 34 (48), 5869-5878, 2015 | 238 | 2015 |
